# AMYLYX PHARMACEUTICALS INC (AMLX)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/AMLX/

- Reporting holders: 6
- Reported value: $367.0K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Valeo Financial Advisors, LLC](https://holderbook.com/funds/1722641-valeo-financial-advisors-llc/) | $293.2K | 10,074 | 0.0% | 7 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $33.1K | 1,139 | 0.0% | 5 |
| [EASTERN BANK](https://holderbook.com/funds/1126395-eastern-bank/) | $21.0K | 721 | 0.0% | 3 |
| [MassMutual Private Wealth & Trust, FSB](https://holderbook.com/funds/1103653-massmutual-private-wealth-trust-fsb/) | $10.3K | 354 | 0.0% | 5 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $9.2K | 316 | 0.0% | 5 |
| [CoreCap Advisors, LLC](https://holderbook.com/funds/1902501-corecap-advisors-llc/) | $262 | 9 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 6 | $367.0K |
| Q2 2026 | 209 | $2.2B |
| Q1 2026 | 174 | $1.6B |
| Q4 2025 | 182 | $1.4B |
| Q3 2025 | 175 | $1.5B |
| Q2 2025 | 132 | $525.6M |
| Q1 2025 | 136 | $262.9M |
| Q4 2024 | 124 | $192.4M |
| Q3 2024 | 112 | $145.4M |
| Q2 2024 | 121 | $87.6M |
| Q1 2024 | 150 | $185.2M |
| Q4 2023 | 185 | $1.0B |